Fake Avastin earlier found in Syria; Merck KGaA cutting across the board; Pfizer buys vitamin C maker;

> Counterfeit versions of Roche's ($RHHBY) cancer drug Avastin that recently surfaced in the U.S. were found in Syria and in Shanghai in the last three years. Story

> American Regent is recalling vials of phenylephrine HCl injection, USP, 1% 5 mL after finding some that contained visible particles. Release

> The Seraing, Belgium, manufacturing facility of contract manufacturer Eurogentec has completed an FDA preapproval inspection and been given acceptable status, thus allowing it to make a bulk parenteral biopharmaceutical for one of its U.S. customers. Item

> Merck KGaA in Germany says it will cut an undisclosed number of jobs across all divisions and all regions to reduce costs. Story

> Expecting to juice its financial results, Pfizer ($PFE) has acquired--for an undisclosed amount--Alacer, the maker of the leading branded vitamin C product in the U.S. Release

> The state-owned Nepal Drugs, which closed in 2011 because of financial losses, will receive a $628,000 loan from the Nepal Finance Ministry to resume production. Story  

> The European Medicines Agency says heparin manufacturers must demonstrate they have traced sources for ingredients to the slaughterhouses. Story

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.